Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
How to buy Reata Pharmaceuticals stock in Canada | $136.74
Own Reata Pharmaceuticals shares in just a few minutes.
Reata Pharmaceuticals is a biotechnology business based in the US. Reata Pharmaceuticals stocks (RETA.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $139.36 – an increase of 7.32% over the previous week. Reata Pharmaceuticals employs 261 staff and has a trailing 12-month revenue of around $8.6 million.
How to buy Reata Pharmaceuticals stock in Canada
- Choose a platform. If you're a beginner, our stock trading table below can help you choose.
- Open your account. You'll need your ID, bank details and national insurance number.
- Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
- Search the platform for stock code: RETA in this case.
- Research Reata Pharmaceuticals stocks. The platform should provide the latest information available.
- Buy your Reata Pharmaceuticals stocks. It's that simple.
What's in this guide?
- Can I buy shares in Reata Pharmaceuticals?
- Has coronavirus impacted Reata Pharmaceuticals shares?
- Reata Pharmaceuticals shares summary
- Compare share dealing platforms
- Is Reata Pharmaceuticals stock a buy or sell?
- Reata Pharmaceuticals performance over time
- Can I short Reata Pharmaceuticals shares?
- Reata Pharmaceuticals's financials
- How volatile are Reata Pharmaceuticals shares?
- Does Reata Pharmaceuticals pay a dividend?
- Other common questions
How has Coronavirus impacted Reata Pharmaceuticals's stock price?
Since the stock market crash in March caused by coronavirus, Reata Pharmaceuticals's stock price has had significant negative movement.
Its last market close was $136.74, which is 35.24% down on its pre-crash value of $211.14 and 21.00% up on the lowest point reached during the March crash when the stocks fell as low as $113.01.
If you had bought $1,000 worth of Reata Pharmaceuticals stocks at the start of February 2020, those stocks would have been worth $536.39 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $567.47.
Reata Pharmaceuticals stock priceUse our graph to track the performance of RETA stocks over time.
Reata Pharmaceuticals stocks at a glance
|Latest market close||$136.74|
|52-week range||$76.34 - $186.817|
|50-day moving average||$139.1821|
|200-day moving average||$116.7071|
|Wall St. target price||$237|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-4.056|
Compare online stock trading platforms
Note: The dollar amounts in the table below are in Canadian dollars.
Is it a good time to buy Reata Pharmaceuticals stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Reata Pharmaceuticals price performance over time
|1 month (2021-06-25)||-8.81%|
|3 months (2021-04-26)||36.64%|
Reata Pharmaceuticals financials
|Revenue TTM||USD$8.6 million|
|Gross profit TTM||USD$-150,061,000|
|Return on assets TTM||-18.07%|
|Return on equity TTM||-89.06%|
|Market capitalisation||USD$4.7 billion|
TTM: trailing 12 months
How to short and sell Reata Pharmaceuticals stocks
- Create a CFD or spread betting account.
- Search for the stock code. E.g. "RETA.US"
- Choose your position size.
- Select "sell" rather than "buy".
- Confirm your position and keep tabs on it. You may wish to set limits on your position.
There are currently 3.8 million Reata Pharmaceuticals stocks held short by investors – that's known as Reata Pharmaceuticals's "short interest". This figure is 9.6% up from 3.5 million last month.
There are a few different ways that this level of interest in shorting Reata Pharmaceuticals stocks can be evaluated.
Reata Pharmaceuticals's "short interest ratio" (SIR)
Reata Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Reata Pharmaceuticals stocks currently shorted divided by the average quantity of Reata Pharmaceuticals stocks traded daily (recently around 486172.58883249). Reata Pharmaceuticals's SIR currently stands at 7.88. In other words for every 100,000 Reata Pharmaceuticals stocks traded daily on the market, roughly 7880 stocks are currently held short.
However Reata Pharmaceuticals's short interest can also be evaluated against the total number of Reata Pharmaceuticals stocks, or, against the total number of tradable Reata Pharmaceuticals stocks (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Reata Pharmaceuticals's short interest could be expressed as 0.11% of the outstanding stocks (for every 100,000 Reata Pharmaceuticals stocks in existence, roughly 110 stocks are currently held short) or 0.1277% of the tradable stocks (for every 100,000 tradable Reata Pharmaceuticals stocks, roughly 128 stocks are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the stock price, with fewer people currently willing to bet against Reata Pharmaceuticals.
Find out more about how you can short Reata Pharmaceuticals stock.
Reata Pharmaceuticals stock dividends
We're not expecting Reata Pharmaceuticals to pay a dividend over the next 12 months. However, you can browse other dividend-paying stocks in our guide.
Reata Pharmaceuticals stock price volatility
Over the last 12 months, Reata Pharmaceuticals's stocks have ranged in value from as little as $76.34 up to $186.817. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a stocks volatility in relation to the market. The market (NASDAQ average) beta is 1, while Reata Pharmaceuticals's is 1.5169. This would suggest that Reata Pharmaceuticals's stocks are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Reata Pharmaceuticals overview
Reata Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation. The company is developing Phase III clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone that is Phase II clinical trial to treat Friedreich's ataxia; and conduct Phase II study for various form of CKD, such as IgA nephropathy, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others. It is also developing RTA 901 for neurological diseases; and RTA 1701 for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases. In addition, the company offers bardoxolone for the treatment of autosomal dominant polycystic kidney disease. Further, it has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; and AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. The company was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005. Reata Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Plano, Texas.
Stocks similar to Reata Pharmaceuticals
Reata Pharmaceuticals in the news
Is Reata Pharmaceuticals, Inc. (RETA) A Good Stock To Buy?
Tracking Baker Brothers Portfolio - Q1 2021 Update
Tracking Stanley Druckenmiller's Duquesne Family Office Portfolio - Q1 2021 Update
Frequently asked questions
More guides on Finder
How to buy Zevia PBC (ZVIA) stock in Canada
Everything we know about the Zevia PBC IPO, plus information on how to buy in.
How to buy Xponential Fitness (XPOF) stock in Canada
Everything we know about the Xponential Fitness IPO, plus information on how to buy in.
How to buy SOPHiA Genetics (SOPH) stock in Canada
Everything we know about the SOPHiA Genetics IPO, plus information on how to buy in.
How to buy Ryan Specialty Group Holdings (RYAN) stock in Canada
Everything we know about the Ryan Specialty Group Holdings IPO, plus information on how to buy in.
How to buy Ocean Biomedical (OCEA) stock in Canada when it goes public
Everything we know about the Ocean Biomedical IPO, plus information on how to buy in.
How to buy Instructure Holdings (INST) stock in Canada
Everything we know about the Instructure Holdings IPO, plus information on how to buy in.
How to buy Gambling.com Group (GAMB) stock in Canada
Everything we know about the Gambling.com Group IPO, plus information on how to buy in.
How to buy Elicio Therapeutics (ELTX) stock in Canada when it goes public
Everything we know about the Elicio Therapeutics IPO, plus information on how to buy in.
How to buy Cytek Biosciences (CTKB) stock in Canada
Everything we know about the Cytek Biosciences IPO, plus information on how to buy in.
How to buy Core & Main (CNM) stock in Canada
Everything we know about the Core & Main IPO, plus information on how to buy in.
Ask an Expert
You must be logged in to post a comment.